AU2004234039A1 - Novel 3,4-disubstituted 1,2,3,6-tetrahydropyridine derivatives - Google Patents

Description

WO 2004/096769 PCT/EP2004/004370 1 Novel 3,4-Disubstituted 1,2,3,6-Tetrahydropyridine Derivatives 5 The invention relates to novel compounds of the general formula I. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more compounds of formula I and especially their use as renin inhibitors in cardiovascular events and renal insufficiency. Furthermore, some of these compounds can be regarded as 10 inhibitors of other aspartyl proteases and might therefore be useful as inhibitors of plasmepsins to treat malaria and as inhibitors of Candida albicans secreted aspartyl proteases to treat fungal infections. In the renin-angiotensin system (RAS) the biologically active angiotensin II (Ang 15 II) is generated by a two-step mechanism. The highly specific enzyme renin cleaves angiotensinogen to angiotensin I (Ang I), which is then further processed to Ang II by the less specific angiotensin-converting enzyme (ACE). Ang II is known to work on at least two receptor subtypes called AT1 and AT2. Whereas AT1 seems to transmit most of the known functions of Ang II, the role of AT2 is 20 still unknown. Modulation of the RAS represents a major advance in the treatment of cardiovascular diseases. ACE inhibitors and AT1 blockers have been accepted to treat hypertension (Waeber B. et al., "The renin-angiotensin system: role in 25 experimental and human hypertension", in Berkenhager W. H., Reid J. L. (eds): Hypertension, Amsterdam, Elsevier Science Publishing Co, 1996, 489-519; Weber M. A., Am. J. Hypertens., 1992, 5, 247S). In addition, ACE inhibitors are used for renal protection (Rosenberg M. E. et al., Kidney International, 1994, 45, 403; Breyer J. A. et al., Kidney International, 1994, 45, S 156), in the prevention 30 of congestive heart failure (Vaughan D. E. et al., Cardiovase. Res., 1994, 28, 159; Fouad-Tarazi F. et al., Am. J. Med., 1988, 84 (Suppl. 3A), 83) and myocardial infarction (Pfeffer M. A. et al., N. Engl. J. Med., 1992, 327, 669).

WO 2004/096769 PCT/EP2004/004370 2 The rationale to develop renin inhibitors is the specificity of renin (Kleinert H. D., Cardiovasc. Drugs, 1995, 9, 645). The only substrate known for renin is angiotensinogen, which can only be processed (under physiological conditions) by renin. In contrast, ACE can also cleave bradykinin besides Ang I and can be by 5 passed by chymase, a serine protease (Husain A., J. Hypertens., 1993, 11, 1155). In patients inhibition of ACE thus leads to bradykinin accumulation causing cough (5-20%) and potentially life-threatening angioneurotic edema (0.1-0.2%) (Israili Z. H. et al., Annals of Internal Medicine, 1992, 117, 234). Chymase is not inhibited by ACE inhibitors. Therefore, the formation of Ang II is still possible in 10 patients treated with ACE inhibitors. Blockade of the AT1 receptor (e.g. by losartan) on the other hand overexposes other AT-receptor subtypes to Ang II, whose concentration is dramatically increased by the blockade of AT1 receptors. This may raise serious questions regarding the safety and efficacy profile of AT, receptor antagonists. In summary, renin inhibitors are not only expected to be 15 different from ACE inhibitors and AT1 blockers with regard to safety, but more importantly also with regard to their efficacy to block the RAS. Only limited clinical experience (Azizi M. et al., J. Hypertens., 1994, 12, 419; Neutel J. M. et al., Am. Heart, 1991, 122, 1094) has been created with renin 20 inhibitors because of their insufficient oral activity due to their peptidomimetic character (Kleinert H. D., Cardiovasc. Drugs, 1995, 9, 645). The clinical development of several compounds has been stopped because of this problem together with the high cost of goods. Only one compound containing four chiral centers has entered clinical trials (Rahuel J. et al., Chem. Biol., 2000, 7, 493; 25 Mealy N. E., Drugs of the Future, 2001, 26, 1139). Thus, metabolically stable, orally bioavailable and sufficiently soluble renin inhibitors that can be prepared on a large scale are missing and sought. Recently, the first non-peptide renin inhibitors were described which show high in vitro activity (Oefner C. et al., Chem. Biol., 1999, 6, 127; Patent Application WO97/09311; Miirki H. P. et al., IIl 30 Farmaco, 2001, 56, 21). However, the development status of these compounds is not known.

WO 2004/096769 PCT/EP2004/004370 3 The present invention relates to the unexpected identification of renin inhibitors of a non-peptidic nature and of low molecular weight. Orally active renin inhibitors of long duration of action which are active in indications beyond blood pressure regulation where the tissular renin-chymase system may be activated leading to 5 pathophysiologically altered local functions such as renal, cardiac and vascular remodeling, atherosclerosis, and possibly restenosis, are described. In particular, the present invention relates to novel compounds of the general formula I. .10 M Q T uV /NH General formula I wherein 15 X and W represent independently a nitrogen atom or a CH-group; V represents -(CH 2 )r-; -A-(CH 2 )s-; -CH 2

-A-(CH

2 )t-; -(CH 2 )s-A-;

-(CH

2

)

2

-A-(CH

2 )u-; -A-(CH 2 )v-B-; -CHz-CH,-CH 2

-A-CH

2 -; -A-CH 2 -CHz-B-CH 2 -; -CHz-A-CH 2

-CH

2 -B-; -CH 2

-CH

2

-CH

2

-A-CH

2

-CH

2 -; -CH 2

-CH

2

-CH

2

-CH

2

-A-CH

2 -; 20 -A-CH 2

-CH

2

-B-CH

2

-CH

2 -; -CH 2

-A-CH

2

-CH

2

-B-CH

2 -; -CH2-A-CH 2

-CH

2

-CH

2 -B-;

-CH

2

-CH

2

-A-CH

2

-CH

2 -B-; A and B independently represent -0-; -S-; -SO-; -SO 2 -; 25 U represents aryl; heteroaryl; WO 2004/096769 PCT/EP2004/004370 4 T represents -CONR'-; -(CH 2 )pOCO-; -(CH 2 )pN(R')CO-; -(CH 2 )pN(R')SO 2 -; -COO-; -(CH 2 )pOCONR -; -(CH 2 )pN(R")CONR'-; Q represents lower alkylene; lower alkenylene; 5 M represents hydrogen; cycloalkyl; aryl; heterocyclyl; heteroaryl; aryl

O(CH

2 )vR2; heteroaryl-O(CH 2 )vR 2 ; aryl-O(CH 2 )20(CH 2 )wR2; heteroaryl

(CH

2 )20(CH 2 )wR 2 ; aryl-OCH 2 CH(Rs)CH 2 R2; heteroaryl- OCH 2 CH(Rs)CH 2 R2; 10 RI and R" independently represent hydrogen; lower alkyl; lower alkenyl; lower alkinyl; cycloalkyl; aryl; cycloalkyl - lower alkyl;

R

2 represents -OH, lower alkoxy, -OCOR 3 , -COOR 3 , -NR 3

R

3 , -OCONR 3

R

3 ', NCONR 3

R

3 ', cyano, -CONR 3

R

3 ', SO 3 H, -SONR 3

R

3 ', -CO-morpholin-4-yl, -CO 15 ((4-loweralkyl)piperazin-1-yl), -NH(NH)NH 2 , -NR 4

R

4 ', with the proviso that a carbon atom is attached at the most to one heteroatom in case this carbon atom is sp 3 -hybridized;

R

3 and R 3 ' independently represent hydrogen; lower alkyl; lower alkenyl; 20 cycloalkyl; cycloalkyl - lower alkyl;

R

4 and R 4 ' independently represent hydrogen; lower alkyl; cycloalkyl; cycloalkyl lower alkyl; hydroxy - lower alkyl; -COOR 2 ; -CONH 2 ; 25 R 5 represents -OH, -OR2; -OCOR 2 ; -OCOOR2; or R 5 and R 2 form together with the carbon atoms to which they are attached a 1,3-dioxolane ring which is substituted in position 2 with R 3 and R 3 '; or R 5 and R 2 form together with the carbon atoms to which they are attached a 1,3-dioxolan-2-one ring; 30 p is the integer 1, 2, 3 or 4; r is the integer 3, 4, 5 or 6; s is the integer 2, 3, 4 or 5; WO 2004/096769 PCT/EP2004/004370 5 t is the integer 1, 2, 3 or 4; u is the integer 1, 2 or 3; v is the integer 2, 3 or 4; w is the integer I or 2; 5 and optically pure enantiomers, mixtures of enantiomers such as racemates, diastereomers, mixtures of diastereomers, diastereomeric racemates, mixtures of diastereomeric racemates, and the meso-form; as well as pharmaceutically acceptable salts, solvent complexes and morphological forms. 10 In the definitions of general formula I - if not otherwise stated - the term lower alkyl, alone or in combination with other groups, means saturated, straight and branched chain groups with one to seven carbon atoms, preferably one to four carbon atoms that can be optionally substituted by halogens. Examples of lower 15 alkyl groups are methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, tert-butyl, pentyl, hexyl and heptyl. The methyl, ethyl and isopropyl groups are preferred. The term lower alkoxy refers to a R-O-groui, wherein R is a lower alkyl. 20 Examples of lower alkoxy groups are methoxy, ethoxy, propoxy, iso-propoxy, iso butoxy, sec-butoxy and tert-butoxy. The term lower alkenyl, alone or in combination with other groups, means straight and branched chain groups comprising an olefinic bond nd-two to seven 25 carbon atoms, preferably two to four carbon atoms, that can be optionally substituted by halogens. Examples of lower alkenyl are vinyl, propenyl or butenyl. The term lower alkinyl, alone or in combination with other groups, means straight 30 and branched chain groups comprising a triple bond and two to seven carbon atoms, preferably two to four carbon atoms, that can be optionally substituted by halogens. Examples of lower alkinyl are ethinyl, propinyl or butinyl.

WO 2004/096769 PCT/EP2004/004370 6 The term lower alkylene, alone or in combination with other groups, means straight and branched divalent chain groups with one to seven carbon atoms, preferably one to four carbon atoms, that can be optionally substituted by halogens. Examples of lower alkylene are ethylene, propylene or butylene. 5 The term lower alkenylene, alone or in combination with other groups, means straight and branched divalent chain groups comprising an olefinic bond and two to seven carbon atoms, preferably two to four carbon atoms, that can be optionally substituted by halogens. Examples of lower alkenylene are vinylene, propenylene 10 and butenylene. The term lower alkylenedioxy, refers to a lower alkylene substituted at each end by an oxygen atom. Examples of lower alkylenedioxy groups are preferably methylenedioxy and ethylenedioxy. 15 The term lower alkylenoxy refers to a lower alkylene substituted at one end by an oxygen atom. Examples of lower alkylenoxy groups are preferably ethylenoxy and propylenoxy. 20 The term halogen means fluorine, chlorine, bromine or iodine, preferably fluorine, chlorine and bromine. The term cycloalkyl alone or in combination, means a saturated cyclic hydrocarbon ring system with 3 to 7 carbon atoms, e.g. cyclopropyl, cyclobutyl, 25 cyclopentyl, cyclohexyl and cycloheptyl, which can be optionally mono-, di-, or trisubstituted independently by lower alkyl, lower alkenyl, lower alkenylene, lower alkoxy, lower alkylenoxy, lower alkylenedioxy, hydroxy, halogen, -CF 3 , -NRIR", -NR 1

C(O)R"

'

, -NRIS(0) 2 R", -C(O)NR'R", lower alkylcarbonyl, COOR' , -SR, -SOR', -SO 2 R', -SO 2 NR'R'. The cyclopropyl group is a preferred 30 group.

WO 2004/096769 PCT/EP2004/004370 7 The term aryl, alone or in combination, relates to the phenyl, the naphthyl or the indanyl group, preferably the phenyl group, which can be optionally mono-, di-, tri-, tetra- or pentasubstituted independently by lower alkyl, lower alkenyl, lower alkinyl, lower alkenylene or lower alkylene forming with the aryl ring a five- or 5 six-membered ring, lower alkoxy, lower alkylenedioxy, lower alkylenoxy, hydroxy, hydroxy-lower alkyl, halogen, cyano, -CF 3 , -OCF 3 , -NR'R", -NR'R" lower alkyl, -NR'C(O)R 1 ', -NRIS(O) 2 R", -C(O)NR'R", -NO 2 , lower alkylcarbonyl, -COOR', -SR', -S(O)R', -S(O) 2 R', -SO 2 NR'R", benzyloxy. Preferred substituents are halogens, lower alkoxy, lower alkyl. 10 The term aryloxy refers to an Ar-O-group, wherein Ar is an aryl. An example of aryloxy groups is phenoxy. The term heterocyclyl, alone or in combination, means saturated or unsaturated 15 (but not aromatic) five-, six- or seven-membered rings containing one or two nitrogen, oxygen or sulfur atoms which may be the same or different and which rings can be optionally substituted with lower alkyl, hydroxy, lower alkoxy and halogen. The nitrogen atoms, if present, can be substituted by a COOR 2 group. Examples of such rings are piperidinyl, morpholinyl, thiomorpholinyl, 20 piperazinyl, tetrahydropyranyl, dihydropyranyl, 1,4-dioxanyl, pyrrolidinyl, tetrahydrofuranyl, dihydropyrrolyl, imidazolidinyl, dihydropyrazolyl, dihydroquinolinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl. The term heteroaryl, alone or in combination, means six-membered aromatic 25 rings containing one to four nitrogen atoms; benzofused six-membered aromatic rings containing one to three nitrogen atoms; five-membered aromatic rings containing one oxygen, one nitrogen or one sulfur atom; benzofused five membered aromatic rings containing one oxygen, one nitrogen or one sulfur atom; five-membered aromatic rings containing one oxygen and one nitrogen atom and 30 benzofused derivatives thereof; five-membered aromatic rings containing a sulfur and a nitrogen or an oxygen atom and benzofused derivatives thereof; five membered aromatic rings containing two nitrogen atoms and benzofused WO 2004/096769 PCT/EP2004/004370 8 derivatives thereof; five-membered aromatic rings containing three nitrogen atoms and benzofused derivatives thereof, or a tetrazolyl ring. Examples of such ring systems are furanyl, thiophenyl, pyrrolyl, pyridinyl, pyrimidinyl, indolyl, quinolinyl, isoquinolinyl, imidazolyl, triazinyl, thiazinyl, thiazolyl, isothiazolyl, 5 pyridazinyl, pyrazolyl, oxazolyl, isoxazolyl, coumarinyl, benzothiophenyl, quinazolinyl, quinoxalinyl. Such rings may be adequatly substituted with lower alkyl, lower alkenyl, lower alkinyl, lower alkylene, lower alkenylene, lower alkylenedioxy, lower alkyleneoxy, hydroxy-lower alkyl, lower alkoxy, hydroxy, halogen, cyano, -CF 3 , -OCF 3 , -NR'R", -NR'R" - lower alkyl, -N(R')COR', 10 -N(R 1

)SO

2 R', -CONR'R"

'

, -NO 2 , lower alkylcarbonyl, -COOR', -SR', -S(O)R', S(O) 2

R

1 , -SO 2 NR'R", another aryl, another heteroaryl or another heterocyclyl and the like. The term heteroaryloxy refers to a Het-O group, wherein Het is a heteroaryl. 15 It is understoood that the substituents outlined relative to the expressions cycloalkyl, heterocyclyl, heteroaryl and aryl have been omitted in the definitions of the general formula I and in claims 1 to 6 for clarity reasons but the definitions in formula I and in claims 1 to 6 should be read as if they are included therein. 20 The expression pharmaceutically acceptable salts encompasses either salts with inorganic acids or organic acids like hydrochloric or hydrobromic acid, sulfuric acid, phosphoric acid, citric acid, formic acid, acetic acid, maleic acid, tartaric acid, benzoic acid, methanesulfonic acid, p-toluenesulfonic acid, and the like that 25 are non toxic to living organisms or in case the compound of formula I is acidic in nature with an inorganic base like an alkali or earth alkali base, e.g. sodium hydroxide, potassium hydroxide, calcium hydroxide and the like. Compounds of the invention also include nitrosated compounds of the general 30 formula I that have been nitrosated through one or more sites such as oxygen (hydroxyl condensation), sulfur (sulffiydryl condensation) and/or nitrogen. The nitrosated compounds of the present invention can be prepared using conventional WO 2004/096769 PCT/EP2004/004370 9 methods known to one skilled in the art. For example, known methods for nitrosating compounds are described in U.S. Pat. Nos. 5,380,758 and 5,703,073; WO 97/27749; WO 98/19672; WO 98/21193; WO 99/00361 and Oae et al, Org. Prep. Proc. Int., 15(3): 165-198 (1983), the disclosures of each of which are 5 incorporated by reference herein in their entirety. The compounds of the general formula I can contain one or more asymmetric carbon atoms and may be prepared in form of optically pure enantiomers, mixtures of enantiomers such as racemates, diastereomers, mixtures of 10 diastereomers, diastereomeric racemates, mixtures of diastereomeric racemates, and the meso-form and pharmaceutically acceptable salts thereof. The present invention encompasses all these forms. Mixtures may be separated in a manner known per se, i.e. by column chromatography, thin layer chromatography, HPLC or crystallization. 15 A group of preferred compounds of general formula I are those wherein X, W, V, and U, are as defined in general formula I wherein T is -CONR-; 20 Q is a methylene; M is aryl; heteroaryl; aryl-O(CH2)vR 2 ; heteroaryl-O(CH 2 )vR 2 . Another group of more preferred compounds of general formula I are those wherein X, W, T, Q, and M are as defined in general formula I wherein 25 V is one of the following groups:

-CH

2

CH

2 0-; -CH 2

CH

2

CH

2 0-; -OCH 2

CH

2 0-; 30 and U is as defined in general formula I above.

WO 2004/096769 PCT/EP2004/004370 10 Another group of even more preferred compounds of general formula I are those wherein V, U, T, Q, and M are as defined in general formula I and wherein X and W represent -CH-. 5 Another group of more preferred compounds of general formula I are those wherein X, W, V, Q, T, and M are as defined in general formula I and wherein U is a mono-, di-, or trisubstituted phenyl or heteroaryl. Preferred substituents are 10 independently halogen, lower alkyl, lower alkoxy, CF 3 . Especially preferred compounds of general formula I are those selected from the group consisting of: (rac.)-4- {4-[3-(2,3,6-trifluorophenoxy)propyl]phenyl } -1,2,3,6-tetrahydropyridine 15 3-carboxylic acid cyclopropyl-(2-fluorobenzyl)amide; (rac.)-4- {4-[3-(2,3,6-trifluorophenoxy)propyl]phenyl } -1,2,3,6-tetrahydropyridine 3-carboxylic acid (2-chlorobenzyl)ethylamide; 20 (rac.)-4- {4-[3-(2,3,6-trifluorophenoxy)propyl]phenyl } -1,2,3,6-tetrahydropyridine 3-carboxylic acid (2-chlorobenzyl)cyclopropylamide; (rac.)-4- {4-[3-(2,3,6-trifluorophenoxy)propyl]phenyl } -1,2,3,6-tetrahydropyridine 3-carboxylic acid cyclopropyl-(2-fluoro-5-methoxybenzyl)amide; 25 (rac.)-4- {4-[3-(2,3,6-trifluorophenoxy)propyl]phenyl } -1,2,3,6-tetrahydropyridine 3-carboxylic acid cyclopropyl-(3-methoxybenzyl)amide; (rac.)-4- {4-[3-(2,3,6-trifluorophenoxy)propyl]phenyl } -1,2,3,6-tetrahydropyridine 30 3-carboxylic acid cyclopropyl-(2-methoxybenzyl)amide; WO 2004/096769 PCT/EP2004/004370 11 (rac.)-4- {4-[3-(2,3,6-trifluorophenoxy)propyl]phenyl } -1,2,3,6-tetrahydro pyridine-3-carboxylic acid cyclopropyl-(5-fluoro-2-methoxybenzyl)amide; (rac.)-4- {4-[3-(2,3,6-trifluorophenoxy)propyl]phenyl } -1,2,3,6-tetrahydropyridine 5 3-carboxylic acid (2-chloro-6-fluorobenzyl)cyclopropylamide; (rac.)-4- {4-[3-(2,3,6-trifluorophenoxy)propyl]phenyl } -1,2,3,6-tetrahydropyridine 3-carboxylic acid (2-bromobenzyl)cyclopropylamide; 10 (rac.)-4- {4-[3-(2,3,6-trifluorophenoxy)propyl]phenyl}-1,2,3,6-tetrahydropyridine 3-carboxylic acid cyclopropyl-(2,3-dimethylbenzyl)amide; (rac.)-4- {4-[3-(2,3,6-trifluorophenoxy)propyl]-henyl } -1,2,3,6-tetrahydro pyridine-3-carboxylic acid (3,5-bis-trifluoromethylbenzyl)cyclopropylamide; 15 (rac.)-4- {4-[3-(2,3 ,6-trifluorophenoxy)propyl]phenyl }-1,2,3 ,6-tetrahydropyridine 3-carboxylic acid (2-chloro-5-trifluoromethylbenzyl)cyclopropylamide; (rac.)-4- {4- [3-(2,3,6-trifluorophenoxy)propyl]phenyl }-1,2,3,6-tetrahydropyridine 3-carboxylic acid (2-chloro-3,6-difluorobenzyl)cyclopropylamide; 20 (rac.)-4- {4-[3-(2,3,6-trifluorophenoxy)propyl]phenyl }-1,2,3,6-tetrahydropyridine 3-carboxylic acid cyclopropyl-(3-methylbenzyl)amide. The compounds of general formula I and their pharmaceutically acceptable salts 25 may be used as therapeutics e.g. in form of pharmaceutical compositions. These pharmaceutical compositions containing at least one compound of general formula I and usual carrier materials and adjuvants may especially be used in the treatment or prophylaxis of disorders which are associated with a dysregulation of the renin angiotensin system (RAS), comprising cardiovascular and renal diseases. 30 Examples of such diseases are hypertension, congestive heart failure, pulmonary heart failure, coronary diseases, cardiac insufficiency, renal insufficiency, renal or myocardial ischemia, atherosclerosis, and renal failure. They can also be used to WO 2004/096769 PCT/EP2004/004370 12 prevent restenosis after balloon or stent angioplasty, to treat erectile dysfunction, glomerulonephritis, renal colic, and glaucoma. Furthermore, they can be used in the therapy and the prophylaxis of diabetic complications, complications after vascular or cardiac surgery, complications of treatment with immunosuppresive 5 agents after organ transplantation, complications of cyclosporin treatment, as well as other diseases presently known to be related to the RAS. In another embodiment, the invention relates to a method for the treatment and/or prophylaxis of diseases which are related to the RAS such as hypertension, 10 congestive heart failure, pulmonary hypertension, cardiac insufficiency, renal insufficiency, renal or myocardial ischemia, atherosclerosis, renal failure, erectile dysfunction, glomerulonephritis, renal colic, glaucoma, diabetic complications, complications after vascular or cardiac surgery, restenosis, complications of treatment with immunosuppresive agents after organ transplantation, and other 15 diseases which are related to the RAS, which method comprises administering a compound according of formula I to a human being or animal. The invention further relates to the use of compounds of general formula I as defined above for the treatment and/or prophylaxis of diseases which are 20 associated with the RAS such as hypertension, congestive heart failure, pulmonary hypertension, cardiac insufficiency, renal insufficiency, renal or myocardial ischemia, atherosclerosis, renal failure, erectile dysfunction, glomerulonephritis, renal colic, glaucoma, diabetic complications, complications after vascular or cardiac surgery, restenosis, complications of treatment with immunosuppresive 25 agents after organ transplantation, and other diseases presently known to be related to the RAS. In addition, the invention relates to the use of compounds as defined above for the preparation of medicaments for the treatment and/or prophylaxis of diseases 30 which are associated with the RAS such as hypertension, coronary diseases, cardiac insufficiency, renal insufficiency, renal and myocardial ischemia, and renal failure. These medicaments may be prepared in a manner known per se.

WO 2004/096769 PCT/EP2004/004370 13 The compounds of formula I may also be used in combination with one or more other pharmacologically active compounds e. g. with other renin inhibitors, with ACE-inhibitors, angiotensin II receptor antagonists, endothelin receptor antagonists, vasodilators, calcium antagonists, potassium activators, diuretics, 5 sympatholitics, beta-adrenergic antagonists, and neutral endopeptidase inhibitors, alpha-adrenergic antagonists, for the treatment of disorders as above-mentioned. All forms of prodrugs leading to an active component comprised in general formula I are included in the present invention. 10 The compounds of general formula I can be manufactured by the methods given below, by the methods given in the examples or by analogous methods. Preparation of the precursors: 15 Precursors are compounds that were prepared as key intermediates and/or building blocks and which were suitable for further transformations in parallel chemistry. Ideal starting materials are any commercially available 4-oxo-piperidine-3 20 carboxylic acid ester derivatives, for instance 1-benzyl-4-oxo-piperidine-3 carboxylic acid methyl ester, possibly as a salt. For practical purposes, a transesterification (for instance according to Seebach D., et al., Synthesis, 1982, 138) to another ester derivative A (wherein Ra is optionally a lower alkyl, a lower alkenyl, or a benzyl group), thereafter a change in the N-protecting group (PG: all 25 abreviations are outlined at the beginning of the chapter Examples) to a derivative of type B, may be necessary (Scheme 1).

WO 2004/096769 PCT/EP2004/004370 14 Scheme 1 0 0 0 0 Ra o o B NN I PG 5 Formation of the vinyl triflate C, followed by a coupling catalysed by a Pd(0) complex leads to tetrahydropyridine derivatives of type D, wherein Rb optionally represents any U-V group as defined in general formula I or a chemical precursor of such a group (Scheme 2).

WO 2004/096769 PCT/EP2004/004370 15 Scheme 2 0 0 OTf 0 0 Ra R B NN C I N PG Rb PG x R X 0 O Ra N I D PG If, for instance, Rb is a linker ending with a silanyl ether, compounds of type D 5 can be deprotected to compounds of type E, then coupled to a phenol or aromatic alcohol using a Mitsunobu reaction, leading to derivatives of type F wherein V and U have the meaning given in general formula I above (Scheme 3). The ester F can then be cleaved under basic conditions to lead to precursor G, whereas the double bond would partially or completely be shifted to the 4,5-position. 10 WO 2004/096769 PCT/EP2004/004370 16 Scheme 3 linker -OH linker -OTBDMS KO 0 R0 0 O Ra / Ra0 E N DI N PPG PG v oU 0e 0R 00ow 0 F OH N I G PG N I PG Other chemistry may be used in analogy to patent applications W003/093267 and 5 WO04/002957. This allows to prepare other compounds included in general formula I.

WO 2004/096769 PCT/EP2004/004370 17 Preparation of final compounds A compound of type G can be coupled to the amine to yield to the corresponding amides wherein V, U and M have the meaning given in general formula I above. 5 Removal of the N-protecting group (PG) leads to the final compounds wherein V, U, Q and M have the meaning given in general formula I above (Scheme 4). If the precursor G is mixed to the corresponding constitutional isomer having a double bond at the 3,4-position, both compounds may be now separated by flash chromatography, using some ammoniac as co-eluent, or by HPLC. 10 Scheme 4 V U V U O O 0 f0 OH N M II G R1 N N II PG PG U V o N M R1 N

H

WO 2004/096769 PCT/EP2004/004370 18 The compounds of formula I and their pharmaceutically acceptable acid addition salts can be used as medicaments, e. g. in the form of pharmaceutical preparations for enteral, parenteral, or topical administration. They can be administered, for example, perorally, e. g. in the form of tablets, coated tablets, drag6es, hard and 5 soft gelatine capsules, solutions, emulsions or suspensions, rectally, e. g. in the form of suppositories, parenterally, e. g. in the form of injection solutions or infusion solutions, or topically, e. g. in the form of ointments, creams or oils. The production of pharmaceutical preparations can be effected in a manner which 10 will be familiar to any person skilled in the art by bringing the described compounds of formula I and their pharmaceutically acceptable acid addition salts, optionally in combination with other therapeutically valuable substances, into a galenical administration form together with suitable, non-toxic, inert, therapeutically compatible solid or liquid carrier materials and, if desired, usual 15 pharmaceutical adjuvants in a manner known per se. Suitable carrier materials are not only inorganic carrier materials, but also organic carrier materials. Thus, for example, lactose, corn starch or derivatives thereof, talc, stearic acid or its salts can be used as carrier materials for tablets, coated 20 tablets, drag6es and hard gelatine capsules. Suitable carrier materials for soft gelatine capsules are, for example, vegetable oils, waxes, fats and semi-solid and liquid polyols (depending on the nature of the active ingredient no carriers are, however, required in the case of soft gelatine capsules). Suitable carrier materials for the production of solutions and syrups are, for example, water, polyols, 25 sucrose, invert sugar and the like. Suitable carrier materials for injections are, for example, water, alcohols, polyols, glycerols and vegetable oils. Suitable carrier materials for suppositories are, for example, natural or hardened oils, waxes, fats and semi-liquid or liquid polyols. Suitable carrier materials for topical preparations are glycerides, semi-synthetic and synthetic glycerides, hydrogenated 30 oils, liquid waxes, liquid paraffins, liquid fatty alcohols, sterols, polyethylene glycols and cellulose derivatives.

WO 2004/096769 PCT/EP2004/004370 19 Usual stabilizers, preservatives, wetting and emulsifying agents, consistency improving agents, flavour-improving agents, salts for varying the osmotic pressure, buffer substances, solubilizers, colorants and masking agents and antioxidants come into consideration as pharmaceutical adjuvants. 5 The dosage of compounds of formula I can vary within wide limits depending on the disease to be controlled, the age and the individual condition of the patient and the mode of administration, and will, of course, be fitted to the individual requirements in each particular case. For adult patients a daily dosage of about 1 10 mg to about 1000 mg, especially about 50 mg to about 500 mg, comes into consideration. For children the dosage has to be adapted to the body weight and age. The pharmaceutical preparations conveniently contain about I - 500 mg, 15 preferably 5 - 200 mg of a compound of formula I. The following examples serve to illustrate the present invention in more detail. They are, however, not intended to limit its scope in any manner. 20 Examples General remarks The following compounds were prepared according to the procedures described 25 for the synthesis of compounds encompassed by the general formula I. All compounds were characterized by 'H-NMR (300 MHz) and occasionally by 13C NMR (75 MHz) (Varian Oxford, 300 MHz; chemical shifts are given in ppm relative to TMS), by LC-MS: A: 2 min < tR < 10 min; (Waters Micromass; ZMD platform with ESI-probe with Alliance 2790 HT; Column: 2x30 mm, Gromsil 30 ODS4, 3 pM, 120A; Gradient: 0 - 100% acetonitril in water, 6 min, with 0.05% formic acid, flow: 0.45 mL/min; tR given in min.), B: 0.1 min < tR < 2 min; (Finnigan AQA with ESI-probe with HP 110 DAD and HP110 binary pump; WO 2004/096769 PCT/EP2004/004370 20 column: Develosil RP-AQUEOUS, 5 tM, 4.6 mm x 50 mm; gradient: 5 - 95% methanol in water (0.04% TFA), 1 min, 95% methanol in water (0.04% TFA) 0.4 min, 4.5 mL/min.), by TLC (TLC-plates from Merck, Silica gel 60 F 2 54 ). Only TLC and LC-MS data are given hereby. 5 Abbreviations ACE Angiotensin Converting Enzyme Ang Angiotensin 10 aq. aqueous Bn Benzyl Boc tert-Butyloxycarbonyl BSA Bovine serum albumine BuLi n-Butyllithium 15 DIPEA Diisopropylethylamine DMAP 4-N,N-Dimethylaminopyridine DMSO Dimethylsulfoxide EDCHCI Ethyl-N,N-dimethylaminopropylcarbodiimide hydrochloride EIA Enzyme immunoassay 20 eq. equivalent Et Ethyl EtOAc Ethyl acetate FC Flash Chromatography HOBt Hydroxybenzotriazol 25 MeOH Methanol org. organic PBS Phosphate Buffer Saline PG protecting group Ph Phenyl 30 RAS Renin Angiotensin System RP18 Reversed phase column, filled with C18 hydrocarbon rt room temperature WO 2004/096769 PCT/EP2004/004370 21 sol. Solution TBDMS tert-Butyldimethylsilyl Tf Trifluoromethylsulfonyl TFA Trifluoroacetic acid 5 THF Tetrahydrofuran TLC Thin Layer Chromatography Preparation of the precursors 10 4-Oxopiperidine-1,3-dicarboxylic acid 1-tert-butyl ester 3-methyl ester (B) A suspension of 1-benzyl-4-oxopiperidine-3-carboxylic acid methyl ester hydrochloride (5.00 g, 17.6 mmol), triethylamine (2.45 mL, 17.6 mmol) and Boc 2 0 (4.20 g, 20.0 mmol) in EtOH (30 mL) was purged with N 2 . Pd/C (10%, 15 600 mg) was added and the suspension purged with H 2 . The reaction mixture was stirred under an H2-atmosphere for 24 h and then filtered through Celite. The filtrate was evaporated under reduced pressure. Purification of the residue by FC (EtOAc/heptane 1:4 --> 2:3) yielded the title compound (4.02 g, 89%). Rf = 0.60 (EtOAc/heptane 1:1). LC-MS: Rt = 1.09 min, ES+ = 202.03. 20 4-Trifluoromethanesulfonyloxy-5,6-dihydro-2H-pyridine-1,3-dicarboxylic acid 1-tert-butyl ester 3-methyl ester (C) To a sol. of compound B (4.00 g, 15.6 mmol) in THF (100 mL) at 0 'C was added 25 NaH (suspension in oil, 55-65%, 1.20 g, about 31 mmol). The suspension was stirred for 30 min at 0 oC and Tf 2 NPh (8.27 g, 23.1 mmol) was added. The ice bath was removed and the reaction mixture stirred for 3 days at rt. Ice was added and the solvents were removed under reduced pressure. The residue was diluted with EtOAc and washed with aq. 10% Na 2

CO

3 . The org. extracts were dried over 30 MgSO 4 , filtered and the solvent removed under reduced pressure. Purification of the residue by FC (EtOAc/heptane 1:4) yielded the title compound (5.19 g, 86%). LC-MS: Rt = 1.17, ES+ = 374.96.

WO 2004/096769 PCT/EP2004/004370 22 4-{4-[3-(tert-Butyldimethylsilanyloxy)propyl]phenyl}-5,6-dihydro-2H pyridine-1,3-dicarboxylic acid 1-tert-butyl ester 3-methyl ester (D) To a sol. of [ 3

-(

4 -bromophenyl)propoxy]-tert-butyldimethylsilane (Kiesewetter D. 5 0., Tetrahedron Asymmetry, 1993, 4, 2183; 6.19 g, 19.7 mmol) in THF (100 mL) at -78 'C was added n-BuLi (1.5M in hexane, 14.0 mL, 21.0 mmol). The sol. was stirred at -78 'C for 30 min and ZnC1 2 (IM in THF, 22.3 mL, 22.3 mmol) was added. The resulting sol. was allowed to warm to rt and compound C (5.10 g, 13.1 mmol) and Pd(PPh 3

)

4 (300 mg, 0.26 mmol) were added. After 20 min at rt 10 ice was added to the reaction mixture. The solvents were removed under reduced pressure and the residue diluted with EtOAc. This mixture was washed with aq. IM NaOH. The org. extracts were dried over MgSO 4 , filtered and the solvents removed under reduced pressure. Purification of the residue by FC (EtOAc/heptane 1:9) led to the title compound (5.77 g, 90%). LC-MS: Rt = 7.27 15 min, ES+ = 512.54. 4-14-(3-Hydroxypropyl)phenyll]-5,6-dihydro-2H-pyridine-1,3-dicarboxylic acid 1-tert-butyl ester 3-methyl ester (E) 20 TBAF (1.90 g, 6.00 mmol) was added to a sol. of compound D (1.95 g, 4.00 mmol) in THF (40 mL). The reaction mixture was stirred for 6 h at rt and diluted with EtOAc. The resulting mixture was washed with water and brine. The org. extracts were dried over MgSO 4 , filtered and the solvents removed under reduced pressure. Purification of the residue by FC (EtOAc/heptane 2:3) yielded the title 25 compound (1.27 g, 84%). LC-MS: Rt = 1.06, ES+ = 376.18. 4-{4-[3-(2,3,6-Trifluorophenoxy)propylj phenyl}-5,6-dihydro-2H-pyridine-1,3 dicarboxylic acid 1-tert-butyl ester 3-methyl ester (F) 30 A sol. of compound E (4.7 g, 12.5 mmol), 2,3,6-trifluorophenol (3.7 g, 25.0 mmol), azodicarboxylic dipiperidine (6.32 g, 34.2 mmol), tri-n-butylphosphine (85%, 9.3 mL, 37.6 mmol) and DIPEA ( 0.035 mL, 0.20 mmoL) in toluene (20 WO 2004/096769 PCT/EP2004/004370 23 mL) was stirred for I h at rt, then for 2 h at 60 oC. The reaction mixture was allowed to cool to rt, was diluted with EtOAc and washed with water. The org. extracts were dried over MgSO 4 , filtered and the solvents were removed under reduced pressure. Purification of the residue by FC (EtOAc/heptane 1:4 -- * 3:7) 5 led to the title compound (5.23 g, 83%). 4-{4-[3-(2,3,6-Trifluorophenoxy)propyl] phenyl}-1,2-dihydro-5H-pyridine-1,3 dicarboxylic acid 1-tert-butyl ester (G) 10 To a sol. of compound F (5.23 g, 10.3 mmol) in EtOH (90 mL) was added aq. IM NaOH (90 mL). The resulting mixture was stirred for 35 min at 80 oC, then allowed to cool to rt. Aq. IM HCl (13 mL) was added and the resulting mixture was extracted with EtOAc (3x). The combined org. extracts were dried over MgSO 4 , filtered and the solvents were removed under reduced pressure. 15 Purification of the residue by FC (EtOAc/heptane 2:3) led to the title compound (4.55 g, 89%). Preparation of the final compounds 20 General procedure A for amide coupling A sol. of the desired carboxylic acid (1.00 eq), the desired amine (2.00 eq), EDC-HCl (1.10 eq.), HOBt (cat. amount), DMAP (cat. amount) and DIPEA (2.00 eq.) in CH 2 C1 2 (20 mL/g of acid) was stirred at rt overnight. The reaction mixture 25 was washed over diatomic earth (Isolute Sorbent Technology, Johnson, C. R., et al., Tetrahedron, 1998, 54, 4097) and the org. extracts were evaporated under reduced pressure. The residue was used without further purification. General procedure B for the removal of a Boc-protecting group 30 The starting material was dissolved in CH 2 C1 2 (10 mL/g of starting material) and the sol. was cooled to 0 'C. 4M HCI in dioxane (same volume as CH 2

CI

2 ) was WO 2004/096769 PCT/EP2004/004370 24 added and the reaction mixture was left for 90 min at rt. The solvents were removed under reduced pressure. Purification of the residue by HPLC led to the desired compound. 5 General procedure Cfor reductive amination To a solution of aldehyde (leq.) in MeOH (0.5 mL/mmol) was added an amine (1.2 eq.). The solution was stirred for 2h. Sodium borohydride (1.2 eq.) was added portionwise at 0 0 C and then stirring was continued, at rt, for 4h. A sol. of aq. I M 10 NaOH was added and the MeOH was evaporated. The mixture was extracted with EtOAc twice and the organic layer was washed with brine, dried over Na 2

SO

4 and filtered. The solvent was removed under reduced pressure. The isolated amines were either used without further purification or purified by flash chromatography (EtOAc/heptane: 2/8), depending on the purity. 15 Preparation of the secondary amines Cyclopropyl(2-fluorobenzyl)amine 20 Synthesized according to general procedure C from 2-fluorobenzaldehyde and cyclopropylamine.

(

2 -Chlorobenzyl)cyclopropylamine 25 Synthesized according to general procedure C from 2-chlorobenzaldehyde and cyclopropylamine. (2-Chlorobenzyl)ethylanmine See Ishihara, Y; et al.; Chem. Pharm. Bull., 1991, 39, 3225. 30 Cyclopropyl-(2-fluoro-5-methoxybenzyl)amine WO 2004/096769 PCT/EP2004/004370 25 Synthesized according to general procedure C from 2-fluoro-5 methoxybenzaldehyde and cyclopropylamine. Cyclopropyl-(3-methoxybenzyl)amine 5 Synthesized according to general procedure C from 3-methoxybenzaldehyde and cyclopropylamine. Cyclopropyl-(2-methoxybenzyl)amine 10 Synthesized according to general procedure C from 2-methoxybenzaldehyde and cyclopropylamine. Cyclopropyl-(5-fluoro-2-methoxybenzyl)amine 15 Synthesized according to general procedure C from 5-fluoro-2 methoxybenzaldehyde and cyclopropylamine. (2-Chloro-6-fluorobenzyl)cyclopropylamine 20 Synthesized according to general procedure C from 2-chloro-6 fluorobenzaldehyde and cyclopropylamine. (2-Bromobenzyl)cyclopropylamine 25 Synthesized according to general procedure C from 2-bromobenzaldehyde and cyclopropylamine. Cyclopropyl-(2,3-dimethylbenzyl)amine 30 Synthesized according to general procedure C from 2,3-dimethylbenzaldehyde and cyclopropylamine.

WO 2004/096769 PCT/EP2004/004370 26

(

3 ,5-Bistrifluoromethylbenzyl)cyclopropylamine Synthesized according to general procedure C from 3,5 bistrifluoromethylbenzaldehyde and cyclopropylamine. 5

(

2 -Chloro-3,6-difluorobenzyl)cyclopropylamine Synthesized according to general procedure C from 2-chloro-3,6 difluorobenzaldehyde and cyclopropylamine. 10 Cyclopropyl-(3-methylbenzyl)amine Synthesized according to general procedure C from 3-methylbenzaldehyde and cyclopropylamine. 15 Examples: Example 1 20 (rac.)-4-{4-[ 3

-(

2

,

3

,

6 -Trifluorophenoxy)propyllphenyl}-1,2,3,6-tetrahydro pyridine-3-carboxylic acid cyclopropyl-(2-fluorobenzyl)amide Prepared according to the general procedures A and B with cyclopropyl-(2 fluorobenzyl)amine. LC-MS: Rt = 0.93; ES+: 539.21. 25 Example 2 (rac.)-4- {4-1 3

-(

2

,

3

,

6 -Trifluorophenoxy)propyl]phenyl}-1,2,3,6-tetrahydro pyridine-3-carboxylic acid (2-chlorobenzyl)ethylamide 30 Prepared according to the general procedures A and B with (2 chlorobenzyl)ethylamine. LC-MS: Rt = 0.94; ES+: 543.17.

WO 2004/096769 PCT/EP2004/004370 27 Example 3 (rac.)-4-{4-[3-(2,3,6-Trifluorophenoxy)propyl]phenyl}-1,2,3,6-tetrahydro pyridine-3-carboxylic acid (2-chlorobenzyl)cyclopropylamide 5 Prepared according to the general procedures A and B with (2 chlorobenzyl)cyclopropylamine. LC-MS: Rt = 0.94; ES+: 555.19. Example 4 10 (rac.)-4-{4-[3-(2,3,6-Trifluorophenoxy)propyl] phenyl}-1,2,3,6-tetrahydro pyridine-3-carboxylic acid cyclopropyl-(2-fluoro-5-methoxybenzyl)amide formate salt 15 Prepared according to the general procedures A and B with cyclopropyl (2-fluoro 5-methoxybenzyl)amine. LC-MS: R, = 0.94; ES+: 569.14. Example 5 20 (rac.)-4-{4-13-(2,3,6-Trifluorophenoxy)propyl]phenyl}-1,2,3,6-tetrahydro pyridine-3-carboxylic acid cyclopropyl-(3-methoxybenzyl)amide formate salt Prepared according to the general procedures A and B with cyclopropyl (3 methoxybenzyl)amine. LC-MS: Rt = 0.93; ES+: 551.18. 25 Example 6 (rac.)-4-{4-[3-(2,3,6-Trifluorophenoxy)propyl]phenyl}-1,2,3,6-tetrahydro pyridine-3-carboxylic acid cyclopropyl-(2-methoxybenzyl)amide formate salt 30 Prepared according to the general procedures A and B with cyclopropyl (2 methoxybenzyl)amine. LC-MS: Rt = 0.94; ES+: 551.18.

WO 2004/096769 PCT/EP2004/004370 28 Example 7 (rac.)-4-{4-[3-(2,3,6-Trifluorophenoxy)propyl]phenyl}-1,2,3,6-tetrahydro pyridine-3-carboxylic acid cyclopropyl-(5-fluoro-2-methoxybenzyl)amide 5 formate salt Prepared according to the general procedures A and B with cyclopropyl (5-fluoro 2-methoxybenzyl)amine. LC-MS: Rt = 0.95; ES+: 569.15. 10 Example 8 (rac.)-4- {4-[3-(2,3,6-Trifluorophenoxy)propyl]phenyl}-1,2,3,6-tetrahydro pyridine-3-carboxylic acid (2-chloro-6-fluorobenzyl)cyclopropylamide formate salt 15 Prepared according to the general procedures A and B with (2-chloro-6 fluorobenzyl)cyclopropylamine. LC-MS: Rt = 0.95; ES+: 573.10. Example 9 20 (rac.)-4-{4-[3-(2,3,6-Trifluorophenoxy)propyl]phenyl}-1,2,3,6-tetrahydro pyridine-3-carboxylic acid (2-bromobenzyl)cyclopropylamide formate salt Prepared according to the general procedures A and B with (2 25 bromobenzyl)cyclopropylamine. LC-MS: Rt = 0.96; ES+: 599.04. Example 10 (rac.)-4-{4-[3-(2,3,6-Trifluorophenoxy)propyl]phenyl}-1,2,3,6-tetrahydro 30 pyridine-3-carboxylic acid cyclopropyl-(2,3-dimethylbenzyl)amide formate salt WO 2004/096769 PCT/EP2004/004370 29 Prepared according to the general procedures A and B with cyclorpopyl-(2,3 dimethylbenzyl)amine. LC-MS: Rt = 0.97; ES+: 549.17. Example 11 5 (rac.)-4-{4-[ 3

-(

2

,

3

,

6 -Trifluorophenoxy)propyl]-henyl}-1,2,3,6-tetrahydro pyridine-3-carboxylic acid ( 3

,

5 -bistrifluoromethylbenzyl)cyclopropylamide formate salt 10 Prepared according to the general procedures A and B with (3,5 bistrifluoromethylbenzyl)cyclopropylamine. LC-MS: Rt = 1.00; ES+: 657.13. Example 12 15 (rac.)-4-{4-[ 3

-(

2 ,3,6-Trifluorophenoxy)propyl]phenyl}-1,2,3,6-tetrahydro pyridine-3-carboxylic acid ( 2 -chloro-3,6-difluorobenzyl)cyclopropylamide formate salt Prepared according to the general procedures A and B with (2-chloro-3,6 20 difluorobenzyl)cyclopropylamine. LC-MS: Rt = 0.96; ES+: 591.12. Example 13 (rac.)-4-{4-[3-(2,3,6-Trifluorophenoxy)propyl]phenyl}-1,2,3,6-tetrahydro 25 pyridine-3-carboxylic acid cyclopropyl-(3-methylbenzyl)amide formate salt Prepared according to the general procedures A and B with cyclopropyl-(3 methylbenzyl)amine. LC-MS: Rt = 0.95; ES+: 535.19. 30 The following assay was carried out in order to determine the activity of the compounds of general formula I and their salts.

WO 2004/096769 PCT/EP2004/004370 30 Inhibition of human recombinant renin by the compounds of the invention The enzymatic in vitro assay was performed in 384-well polypropylene plates 5 (Nunc). The assay buffer consisted of 10 mM PBS (Gibco BRL) including 1 mM EDTA and 0.1% BSA. The incubates were composed of 50 pL per well of an enzyme mix and 2.5 gL of renin inhibitors in DMSO. The enzyme mix was premixed at 4oC and consists of the following components: * human recombinant renin (0.16 ng/mL) 10 * synthetic human angiotensin(l-14) (0.5 pM) * hydroxyquinoline sulfate (1 mM) The mixtures were then incubated at 37 0 C for 3 h. To determine the enzymatic activity and its inhibition, the accumulated Ang I was detected by an enzyme immunoassay (EIA) in 384-well plates (Nunc). 5 .L of the 15 incubates or standards were transferred to immuno plates which were previously coated with a covalent complex of Ang I and bovine serum albumin (Ang I BSA). 75 4L of Ang I-antibodies in assay buffer above including 0.01% Tween 20 were added and a primary incubation made at 4 oC overnight. The plates were washed 3 times with PBS including 0.01% Tween 20, and then incubated for 2 h 20 at rt with an antirabbit-peroxidase coupled antibody (WA 934, Amersham). After washing the plates 3 times, the peroxidase substrate ABTS (2.2'-azino-di-(3-ethyl benzthiazolinsulfonate), was added and the plates incubated for 60 min at rt. After stopping the reaction with 0.1 M citric acid pH 4.3 the plate was evaluated in a microplate reader at 405 nm. The percentage of inhibition was calculated of each 25 concentration point and the concentration of renin inhibition was determined that inhibited the enzyme activity by 50% (IC 5 o). The IC 5 0 -values of all compounds tested are below 1 pM. Selected compounds exhibit a very good bioavailibility and are metabolically more stable than prior art compounds.

Claims (10)

1. Compounds of the general formula I M Q T V NH General formula I 5 wherein X and W represent independently a nitrogen atom or a CH-group; 10 V represents -(CH 2 )r,-; -A-(CH 2 )s-; -CH 2 -A-(CH 2 )t-; -(CH 2 )s-A-; -(CH 2 ) 2 -A-(CH 2 )u-; -A-(CH 2 )v-B-; -CH 2 -CH 2 -CH 2 -A-CH 2 -; -A-CH 2 -CH 2 -B-CH 2 -; -CH 2 -A-CH 2 -CH 2 -B-; -CH 2 -CHz-CH 2 -A-CH 2 -CH 2 -; -CH 2 -CH 2 -CH 2 -CH 2 -A-CH 2 -; -A-CH 2 -CH 2 -B-CH 2 -CH 2 -; -CH 2 -A-CH 2 -CH 2 -B-CH 2 -; -CH 2 -A-CH 2 -CH 2 -CH 2 -B-; -CH 2 -CH 2 -A-CH 2 -CH 2 -B-; 15 A and B independently represent -0- ; -S-; -SO-; -SO2-; U represents aryl; heteroaryl; 20 T represents -CONR'-; -(CH 2 )pOCO-; -(CH 2 )pN(R')CO-; -(CH 2 )pN(R')SO 2 -; -COO-; -(CH 2 )pOCONR'-; -(CH 2 )pN(R 1 ')CONR'-; Q represents lower alkylene; lower alkenylene; WO 2004/096769 PCT/EP2004/004370 32 M represents hydrogen; cycloalkyl; aryl; heterocyclyl; heteroaryl; aryl O(CH 2 )vR 2 ; heteroaryl-O(CH 2 )vR 2 ; aryl-O(CH 2 ) 2 0(CH 2 )wR 2 ; heteroaryl (CH 2 ) 2 0(CH 2 )wR2; aryl-OCH 2 CH(RS)CH 2 R2; heteroaryl- OCH 2 CH(Rs)CH 2 R2; 5 R' and R" independently represent hydrogen; lower alkyl; lower alkenyl; lower alkinyl; cycloalkyl; aryl; cycloalkyl - lower alkyl; R 2 represents -OH, lower alkoxy, -OCOR 3 , -COOR 3 , -NR R , -OCONR R 3 ', -NCONR 3 R ', cyano, -CONR 3 R 3 ', SO 3 H, -SONR 3 R 3 ', -CO-morpholin-4-yl, -CO 10 ((4-loweralkyl)piperazin-1-yl), -NH(NH)NH 2 , -NR 4 R 4 ', with the proviso that a carbon atom is attached at the most to one heteroatom in case this carbon atom is sp 3 -hybridized; R 3 and R 3 ' independently represent hydrogen; lower alkyl; lower alkenyl; 15 cycloalkyl; cycloalkyl - lower alkyl; R 4 and R 4 ' independently represent hydrogen; lower alkyl; cycloalkyl; cycloalkyl lower alkyl; hydroxy - lower alkyl; -COOR ; -CONH 2 ; 20 R 5 represents -OH, -OR2; -OCOR 2 ; -OCOOR2; or R 5 and R 2 form together with the carbon atoms to which they are attached a 1,3-dioxolane ring which is substituted in position 2 with R 3 and R 3 '; or R s and R 2 form together with the carbon atoms to which they are attached a 1,3-dioxolan-2-one ring; 25 p is the integer 1, 2, 3 or 4; r is the integer 3, 4, 5, or 6; s is the integer 2, 3, 4 or 5; t is the integer 1, 2, 3 or 4; u is the integer 1, 2 or 3; 30 v is the integer 2, 3 or 4; w is the integer 1 or 2; WO 2004/096769 PCT/EP2004/004370 33 and optically pure enantiomers, mixtures of enantiomers such as racemates, diastereomers, mixtures of diastereomers, diastereomeric racemates, mixtures of diastereomeric racemates, and the meso-form; as well as pharmaceutically acceptable salts, solvent complexes and morphological forms. 5

2. Compounds of general formula I according to claim 1 wherein X, W, V, and U are as defined in general formula I wherein T represents -CONR'-; 10 Q represents a methylene; M represents aryl; heteroaryl; aryl-O(CH 2 )vR 2 ; heteroaryl-O(CH 2 )vR 2 ; and optically pure enantiomers, mixtures of enantiomers such as racemates, diastereomers, mixtures of diastereomers, diastereomeric racemates, mixtures of 15 diastereomeric racemates, and the meso-form; as well as pharmaceutically acceptable salts, solvent complexes and morphological forms.

3. Compounds of general formula I according to claim 1 wherein X, W, T, Q, and M are as defined in general formula I wherein 20 V represents -CH 2 CH 2 0-; -CH 2 CH2CH 2 0-; -OCH 2 CH 2 0-; 25 and U is as defined in general formula I, and optically pure enantiomers, mixtures of enantiomers such as racemates, diastereomers, mixtures of diastereomers, diastereomeric racemates, mixtures of diastereomeric racemates, and the meso-form; as well as pharmaceutically 30 acceptable salts, solvent complexes and morphological forms. WO 2004/096769 PCT/EP2004/004370 34

4. Compounds of general formula I according to claim 1 wherein V, U, T, Q, and M are as defined in general formula I above, wherein X and W represent -CH-; 5 and optically pure enantiomers, mixtures of enantiomers such as racemates, diastereomers, mixtures of diastereomers, diastereomeric racemates, mixtures of diastereomeric racemates, and the meso-form; as well as pharmaceutically acceptable salts, solvent complexes and morphological forms. 10

5. Compounds of general formula I according to claim 1 wherein X, W, V, Q, T, and M are as defined in general formula I above, wherein U represents a mono-, di-, or trisubstituted phenyl or heteroaryl, wherein the 15 substituents are independently halogen, lower alkyl, lower alkoxy, CF 3 ; and optically pure enantiomers, mixtures of enantiomers such as racemates, diastereomers, mixtures of diastereomers, diastereomeric racemates, mixtures of diastereomeric racemates, and the meso-form; as well as pharmaceutically 20 acceptable salts, solvent complexes and morphological forms.

6. The compounds according to any one of claims I to 5 selected from the group consisting of 25 (rac.)-4- {4-[3-(2,3 ,6-trifluorophenoxy)propyl]phenyl} -1,2,3 ,6-tetrahydropyridine 3-carboxylic acid cyclopropyl-(2-fluorobenzyl)amide; (rae.)-4- {4-[3 -(2,3,6-trifluorophenoxy)propyl]phenyl } -1,2,3,6-tetrahydropyridine 3-carboxylic acid (2-chlorobenzyl)ethylamide; 30 (rac.)-4- {4-[3-(2,3,6-trifluorophenoxy)propyl]phenyl} -1,2,3,6-tetrahydropyridine 3-carboxylic acid (2-chlorobenzyl)cyclopropylamide; WO 2004/096769 PCT/EP2004/004370 35 (rac.)-4- {4- [3-(2,3,6-trifluorophenoxy)propyl]phenyl } -1,2,3,6-tetrahydropyridine 3-carboxylic acid cyclopropyl-(2-fluoro-5-methoxybenzyl)amide; (rac.)-4- {4-[3-(2,3,6-trifluorophenoxy)propyl]phenyl }-1,2,3,6-tetrahydropyridine 5 3-carboxylic acid cyclopropyl-(3-methoxybenzyl)amide; (rac.)-4- {4-[3-(2,3,6-trifluorophenoxy)propyl]phenyl }-1,2,3,6-tetrahydropyridine 3-carboxylic acid cyclopropyl-(2-methoxybenzyl)amide; 10 (rac.)-4- {4-[3-(2,3,6-trifluorophenoxy)propyl]phenyl)-1,2,3,6-tetrahydro pyridine-3-carboxylic acid cyclopropyl-(5-fluoro-2-methoxybenzyl)amide; (rac.)-4- {4-[3-(2,3,6-trifluorophenoxy)propyl]phenyl)-1,2,3,6-tetrahydropyridine 3-carboxylic acid (2-chloro-6-fluorobenzyl)cyclopropylamide; 15 (rac.)-4- {4-[3-(2,3,6-trifluorophenoxy)propyl]phenyl }-1,2,3,6-tetrahydropyridine 3-carboxylic acid (2-bromobenzyl)cyclopropylamide; (rac.)-4- {4-[3-(2,3,6-trifluorophenoxy)propyl]phenyl }-1,2,3,6-tetrahydropyridine 20 3-carboxylic acid cyclopropyl-(2,3-dimethylbenzyl)amide; (rac.)-4- {4-[3-(2,3,6-trifluorophenoxy)propyl]-henyl }-1,2,3,6-tetrahydro pyridine-3-carboxylic acid (3,5-bis-trifluoromethylbenzyl)cyclopropylamide; 25 (rac.)-4- {4-[3-(2,3,6-trifluorophenoxy)propyl]phenyl -1,2,3,6-tetrahydropyridine 3-carboxylic acid (2-chloro-5-trifluoromethylbenzyl)cyclopropylamide; (rac.)-4- {4-[3-(2,3,6-trifluorophenoxy)propyl]phenyl}-1,2,3,6-tetrahydropyridine 3-carboxylic acid (2-chloro-3,6-difluorobenzyl)cyclopropylamide; 30 (rac.)-4- {4-[3-(2,3,6-trifluorophenoxy)propyl]phenyl }-1,2,3,6-tetrahydropyridine 3-carboxylic acid cyclopropyl-(3-methylbenzyl)amide. WO 2004/096769 PCT/EP2004/004370 36

7. Pharmaceutical compositions containing at least one compound of any ones of claims 1 to 6 and usual carrier materials and adjuvants for the treatment or prophylaxis of disorders which are associated with a dysregulation of the renin angiotensin system (RAS), comprising cardiovascular and renal diseases, 5 hypertension, congestive heart failure, pulmonary hypertension, cardiac insufficiency, renal insufficiency, renal or myocardial ischemia, atherosclerosis, renal failure, erectile dysfunction, glomerulonephritis, renal colic, glaucoma, diabetic complications, complications after vascular or cardiac surgery, restenosis, complications of treatment with immunosuppresive agents after organ 10 transplantation, and other diseases presently known to be related to the RAS.

8. A method for the treatment or prophylaxis of diseases which are related to the RAS including hypertension, congestive heart failure, pulmonary hypertension, cardiac insufficiency, renal insufficiency, renal or myocardial ischemia, 15 atherosclerosis, renal failure, erectile dysfunction, glomerulonephritis, renal colic, glaucoma, diabetic complications, complications after vascular or cardiac surgery, restenosis, complications of treatment with immunosuppresive agents after organ transplantation, and other diseases which are related to the RAS, which method comprises administering a compound according to any one of claims 1 to 6 to a 20 human being or animal.

9. The use of compounds according to any one of claims 1 to 6 for the treatment or prophylaxis of diseases which are associated with the RAS comprising hypertension, congestive heart failure, pulmonary hypertension, cardiac 25 insufficiency, renal insufficiency, renal or myocardial ischemia, atherosclerosis, renal failure, erectile dysfunction, glomerulonephritis, renal colic, glaucoma, diabetic complications, complications after vascular or cardiac surgery, restenosis, complications of treatment with immunosuppresive agents after organ transplantation, and other diseases presently known to be related to the RAS. 30

10. The use of one or more compounds of any one of claims I to 6 in combination with other pharmacologically active compounds comprising ACE inhibitors, WO 2004/096769 PCT/EP2004/004370 37 angiotensin II receptor antagonists, endothelin receptor antagonists, vasodilators, calcium antagonists, potassium activators, diuretics, sympatholitics, beta adrenergic antagonists, alpha-adrenergic antagonists, and neutral endopeptidase inhibitors, for the treatment of disorders given in any one of claims 7 to 9. 5